Moderate-to-Severe Psoriasis
Conditions
Interventions
Xeligekimab group:None
Sponsors
Chongqing Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years, male or female; 2.Diagnosed with moderate to severe plaque psoriasis 3.Considered by the investigator to be a candidate for initial treatment with Xeligekimab 4.Voluntary participation and signed informed consent form.
Exclusion criteria
Exclusion criteria: 1.Drug-induced psoriasis at screening or baseline (e.g., psoriasis onset or exacerbation due to beta-blockers, calcium channel blockers, lithium, etc.); 2.Presence of other inflammatory diseases, including but not limited to inflammatory bowel disease, which in the investigator’s judgment may affect efficacy or safety assessments; 3.Patients with currently treated or untreated malignant tumors; 4.History of severe hypersensitivity to the active ingredient or any excipient of Setokimab injection; 5.Active infection of clinical significance; 6.Pregnant or lactating women; 7.History of severe psychiatric disorder or family history thereof; 8.Patients with other contraindications as per the prescribing information; 9.Any other condition considered by the investigator to make the patient unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASI 90 response; | — |
Secondary
| Measure | Time frame |
|---|---|
| PASI 90 response;DLQI 0/1 response;PGA(0/1)response;Median time to achieve PASI 75 response in patients;PASI75 response;PASI 100 response;Median time to achieve PASI 90 response in patients;Median time to achieve PASI 100 response in patients; | — |
Countries
China
Contacts
Public ContactDiao Qingchun/Wang Qin
Chongqing Hospital of Traditional Chinese Medicine
Outcome results
None listed